Clostridial toxin derivatives and methods for treating pain
View Patent ↗Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.
1. An agent for treating pain comprising a modified botulinum neurotoxin comprising a botulinum neurotoxin H N , a botulinum neurotoxin L chain, and no functional H C domain, the modified botulinum neurotoxin being covalently coupled to substance P so that the modified botulinum neurotoxin no longer binds to botulinum neurotoxin receptors at a neuromuscular junction with the same affinity as the native botulinum neurotoxin.
2. The agent of claim 1 , wherein the botulinum neurotoxin is a botulinum toxin selected from the group consisting of serotype A, serotype B, serotype C 1 , serotype D, serotype E, serotype F and serotype G.
3. The agent of claim 1 , wherein the botulinum neurotoxin is botulinum toxin serotype A.
4. The agent of claim 1 , wherein the agent is a fusion protein.
5. The agent of claim 1 , wherein the L chain is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C 1 , serotype D, serotype E, serotype F and serotype G.
6. The agent of claim 1 , wherein the H N is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C 1 , serotype D, serotype E, serotype F and serotype G.